Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Japan / NCT02848274
Recruiting Observational

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

NCT02848274 · tracked via the Priya Life Science Japan tracker
Sponsor
Stanford University
Phase
Observational
Started
2016-10
Last updated
2025-10-22

Condition(s) studied

Mycosis FungoidesNon-Hodgkin's Lymphoma

Study summary

The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will enable the identification of low- and high-risk groups for survival in order to improve patient care and outcome.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria * Diagnosis of advanced stage MF or SS (Stages IIB - IVB) within 6 months of presentation to the participating center * Patients that are expected to have care administered at the participating center or jointly with referring physician(s) where follow-up data would be available Exclusion Criteria * Patients diagnosed with early stage MF/SS (Stages IA-IIA) before progressing to advanced stage * Patients diagnosed with advanced MF/SS more than 6 months prior to initial presentation to the participating center * Exclude one-time consultation type of new patients.

Primary outcome measure(s)

  • Overall survival (OS) — date of diagnosis to death from any cause, up to two years

Trial sites (13)

FacilityCityRegionStatus
City of Hope Duarte California Recruiting
Stanford University, School of Medicine Palo Alto California Recruiting
University of Iowa Iowa City Iowa Recruiting
Hackensack University Medical Center Hackensack New Jersey Recruiting
University of Pittsburg Pittsburgh Pennsylvania Recruiting
University of Texas Southwestern Dallas Texas Recruiting
University of Utah Hospital Salt Lake City Utah Recruiting
Hospital Italiano de Buenos Aires Buenos Aires Argentina Recruiting
Peter MacCallum Cancer Center, Melbourne Australia Recruiting
University of Sao Paulo Medical School São Paulo Brazil Recruiting
Peking University First Hospital Beijing China Recruiting
The University of Tokyo Tokyo Japan Recruiting
University Hospitals Birmingham Birmingham United Kingdom Recruiting

Other trials for the same condition

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Active, not recruiting
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT02848274 on ClinicalTrials.gov ↗ ← All trials in Japan